Actinium Pharmaceuticals Inc Sustainability Reports
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapies for cancer treatment. The company utilizes its proprietary Antibody Radiation Conjugates platform to combine monoclonal antibodies with radioisotopes to selectively destroy cancer cells.
Sector: Manufacturing
Country: United States
Exchange: NYSE American
ISIN: US00507W2061
6 reports from 2020 to 2025